The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma)


The Scleroderma bioreposiTOry and Pathogenesis Study (STOP Scleroderma) will help researchers use clinical data and human biospecimens to investigate why scleroderma patients develop certain complications from their disease. Patients with confirmed scleroderma, raynauds or positive autoantibodies are invited to participate. This research may help us understand how to prevent and treat scleroderma and other diseases.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: July 2034

Clinical Trial Outcome Measures

Primary Measures

  • Modified Rodnan Skin Score
    • Time Frame: 10 years

Secondary Measures

  • Medsger Severity Score
    • Time Frame: 10 years

Participating in This Clinical Trial

Inclusion Criteria

  • Age >18 years – Able to give informed consent. – Diagnosed with scleroderma or with positive autoantibodies Exclusion Criteria:

  • < 18 years old

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 100 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • George Washington University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Victoria Shanmugam, Professor of Medicine – George Washington University
  • Overall Official(s)
    • Victoria K Shanmugam, MD, Principal Investigator, The George Washington University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.